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Previous research has observed elevated rates of OSA observed in individuals 
with PTSD compared to the general population. Retrospective studies suggest that 
successful treatment of OSA in individuals with PTSD is related to reductions in 
nightmares and overall PTSD symptom severity. The purpose of the current study was to 
extend this research by prospectively examining PTSD sympomatology in a sample of 
Veterans initiating treatment for OSA. Participants were 47 Veterans presenting to a 
VAMC Neurology Sleep Clinic for overnight polysomnography. Veterans were eligible 
if they were: (a) diagnosed with OSA; (b) received continuous positive airway pressure 
(CPAP) treatment; and (c) had a minimum score of 25 on the baseline administration of 
the PCL.  The majority of the sample were male (n = 42; 89.4%) and Caucasian (n = 23; 
48.9%) or African American (n = 22; 46.8%), with a mean age of 53.5 years.  Veterans 
completed self-report questionnaires across two pre-treatment and two post-treatment 
(two weeks and four weeks from treatment initiation) time points. A 2 (treatment 
compliance status) x 4 (time) mixed model repeated measures analysis was conducted on 
PTSD symptom severity as measured by the PCL administered at each time point. A 
statistically significant compliance status x time interaction emerged, (F(3, 102.15) = 
5.66. p = .001) such that CPAP-compliant Veterans reported a statistically significant 
reduction in PTSD symptoms from pre to post-treatment, whereas CPAP non-compliant 
Veterans did not. These findings suggest that successful treatment of a physical sleep 
disorder like OSA is associated with a subsequent reduction of posttraumatic distress.  
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A Prospective Evaluation of PTSD Symptoms Following CPAP Treatment for Sleep-
Disordered Breathing in Veterans 
The diagnosis of posttraumatic stress disorder (PTSD) denotes psychological 
symptoms across three broad domains: re-experiencing, avoidance/numbing, and 
hyperarousal (DSM-IV-TR; APA, 2000). Although not unique to PTSD, sleep problems 
are a salient aspect of this diagnosis and are characterized by persistent nightmares as 
well as onset and/or maintenance insomnia (Ross, Ball, Sullivan, & Caroff, 1989). These 
sleep-related symptoms are conceptualized as distinct from each other, whereby the 
occurrence of nightmares (“recurrent distressing dreams”) is designated as a re-
experiencing symptom and sleep initiation/maintenance difficulties reflect hyperarousal 
(APA, 2000). Individuals with PTSD frequently report sleep initiation difficulties, 
frequent mid-sleep awakenings, awakenings accompanied by panic or startle, and 
nightmares (Harvey, Jones, Schimdt, 2003; Mellman, Kulick-Bell, Ashlock, & Nolan, 
1995).  
 Although sleep disturbance in the context of PTSD may occur as a symptom of 
the disorder, it may also occur as an independent phenomenon, in some cases pre-dating 
other PTSD symptoms. And the relationship between PTSD and dysfunctional sleep 
processes appears to be reciprocal. It is well documented that individuals with PTSD are 
at elevated risk for sleep disturbance (see reviews: Germain, 2009; Harvey et al., 2003; 
Maher, Rego, & Asnis, 2006; Pillar, Malhotra, & Lavie, 2000) with the severity of 
disturbed sleep directly proportional to the level of PTSD symptom severity (Germain, 
Buysse, Shear, Fayyad, & Austin, 2004; Krakow et al., 2001). A large majority (70-91%) 
of individuals with PTSD report some sleep-related dysfunction (Maher et al., 2006). 





onset (Koren, Arnon, Lavie, & Klein, 2002) and is associated with more severe PTSD 
symptomatology overall (Krakow et al., 2004; Lavie, 2006; Maher et al., 2006). It 
appears then that sleep dysfunction can manifest as both an antecedent to and a 
consequence of PTSD; however, the majority of extant research has focused on sleep 
disturbance as a result of PTSD.  
Despite extensive research on sleep disturbance and PTSD, one factor that has 
received little attention in the literature to date is the co-occurrence of sleep-disorder 
breathing (SDB) in individuals with PTSD. The SDB label has been used to refer to a 
group of organic sleep disorders which cause a repetitive disruption to the respiratory 
process during sleep. Relative to the general population, individuals with PTSD seem to 
be at higher risk for SDB (Bixler et al., 2001; Maher et al., 2006). Unfortunately, few 
studies that have examined sleep-related difficulties in individuals with PTSD have 
concurrently examined SDB as a possible antecedent (Pillar et al., 2000). Interestingly, 
retrospective studies suggest that successful treatment of SBD in individuals with PTSD 
is associated with an improvement in nightmares and overall PTSD symptoms (Krakow 
et al., 2000; Youakim, Doghramji, Schutte, 1998); however no studies have examined 
prospectively whether changes in PTSD symptomatology occur following successful 
treatment of SDB. 
Disturbed Sleep and PTSD 
 As previously noted, higher rates of self-reported sleep disturbance have been 
well-documented among individuals with PTSD compared to those without. Sleep 
problems have been observed in a number of studies of individuals diagnosed with PTSD 





sexual assault survivors (Foa, Riggs, & Gershuny, 1995), motor vehicle accident (MVA) 
survivors (Harvey & Bryant, 1998; Koren, Arnon, Lavie, & Ehud, 2002), and survivors 
of natural disaster (Mellman et al., 1995; Sharan, Chaudhary, Kavathekar, & Saxena, 
1996). Although many studies have employed self-report methods to assess sleep 
disturbance, the gold standard for measuring sleep processes and diagnosing sleep 
disorders is polysomnography (PSG). PSG uses psychophysiological instruments to 
measure brain activity during sleep. PSG provides objective data regarding sleep episode 
characteristics such as total sleep time, number of awakenings, and time spent in the 
various stages. Although self-report studies have overwhelmingly suggested that PTSD is 
associated with various sleep-related disturbances, studies that have used PSG to examine 
sleep processes in PTSD have been less consistent in their findings (Breslau et al., 2004; 
Klein, Koren, Arnon, & Lavie, 2002). In fact, the majority of studies using PSG have not 
found a statistically significant difference in the rates of sleep disturbances for individuals 
with PTSD compared to those without (Breslau et al., 2004; Fuller, Waters, & Scott, 
1994; Klein, Koren, Arnon, & Lavie; 2002; Lavie, Katz, Pillar, & Zinger, 1998; 
Mellman, Bustamante, Fins, Pigeon, & Nolan, 2002; Mellman, David, Kulick-Bell, 
Hebding, & Nolan, 1995; Neylan et al., 2003; & Otte et al., 2007). 
Despite the apparent lack of congruence among studies using objective vs. 
subjective assessment, sleep dysfunction has long been considered a hallmark feature of 
PTSD pathology (Ross et al., 1989). As previously noted, the relationship between 
disturbed sleep and PTSD appears to be reciprocal. Previous research has suggested that 
disturbed sleep in the wake of trauma is a risk factor for future PTSD development and 





the presence of both sleep disturbance and nightmares following trauma predicted PTSD 
in a sample of 158 female assault victims. The presence of trauma-related nightmares 
following life-threatening injury was also associated with PTSD symptoms severity in a 
sample of 60 patients hospitalized in a regional trauma unit (Mellman, David, 
Bustamante, Torres, & Fins, 2001).  
Although the implications of these findings are limited to some extent by cross-
sectional design, other prospective research has similarly demonstrated that disturbed 
sleep is predictive of PTSD onset and PTSD symptom severity. Koren and colleagues 
(2002) assessed 102 MVA survivors longitudinally for one year following their MVA. 
Their findings revealed that a majority of the survivors experienced sleep difficulties 
immediately following the accident; however, the severity of sleep difficulty was 
predictive of later PTSD diagnosis (Koren et al., 2002). A comparable finding was 
reported in a separate sample of MVA survivors such that both disturbed sleep and the 
presence of nightmares one month following trauma predicted PTSD development six 
months later (Harvey & Bryant, 1998). A more recent prospective study demonstrated 
that sleep disturbance immediately prior to trauma exposure also increased risk for the 
future development of PTSD (Bryant, Creamer, O’Donnell, Silove, & McFarlane, 2010). 
In this study, a sample of traumatically injured hospital patients (N = 1033) were assessed 
at the time of injury for current psychiatric disorders, including sleep dysfunction. Results 
found that pre-trauma disturbed sleep predicted future onset of PTSD after controlling for 






Overall, the research suggests that disturbed sleep is common among individuals 
with PTSD and may contribute to the maintenance of PTSD symptoms. Given the 
apparent reciprocal nature of this relationship, an important goal for researchers is to 
better understand the relation between disturbed sleep and PTSD. One factor that has 
been largely excluded from this research base is the co-occurrence of sleep-disordered 
breathing (SDB) in individuals with PTSD. Elevated rates of SDB have been observed 
among individuals with PTSD (Krakow et al., 2000; Krakow et al., 2001); however, 
many studies that have examined sleep-related difficulties in individuals with PTSD have 
excluded individuals on the basis of a sleep-disordered breathing diagnosis. The 
exclusion of SDB as a source of sleep disruption is important to recognize as individuals 
with PTSD likely experience both psychogenic and organically manifested sleep 
disturbance. Unfortunately, large proportions of individuals with a sleep-breathing 
disorder are unaware of the underlying condition (Punjabi, 2008) and attribute ongoing 
sleep difficulties to other factors. SDB may be an important factor contributing to the 
high rates sleep disturbance reported, but not objectively observed in individuals with 
PTSD, as well as a potent risk factor increasing a trauma survivors’ vulnerability to 
develop clinically significant PTSD symptoms.  
Sleep Disordered Breathing 
Sleep-disordered breathing refers to a repetitive disruption of the respiratory 
process during sleep. This disruption is generally attributed to an obstruction of the 
airway and each interruption, referred to as an apnea, restricts airflow resulting in one or 
more consecutively missed breaths. Although not all SDB is associated with subsequent 





that clinically significant SDB is defined as five or more episodes of apnea per hour of 
sleep (Flemons, 2002). When this clinically significant sleep-disordered breathing is 
accompanied by snoring as well as daytime sleepiness or fatigue the individual is at risk 
for sleep apnea syndrome. The most prevalent form of sleep apnea is obstructive sleep 
apnea (OSA). OSA is characterized by a complete or partial obstruction to the upper 
respiratory tract during sleep that occurs despite adequate respiratory effort. Common 
risk factors for OSA include increasing age, obesity, large neck circumference, 
craniofacial abnormalities, and genetic predisposition (Levitzky, 2008; Punjabi, 2008). 
For some individuals suffering from OSA, the sleep architecture is significantly altered, 
including almost complete deprivation to rapid eye movement (REM) stage sleep as well 
as stage 3 and stage 4 (deep) sleep due to repeated mid-sleep awakenings. Consequently, 
individuals with OSA experience daytime sleepiness and fatigue; however, they may be 
unaware of the cause.  
Obstructive sleep apnea is associated with a range of negative outcomes. In 
addition to fragmented sleep architecture and daytime fatigue, individuals suffering from 
OSA are at risk for impaired memory, cognitive dysfunction, and significant medical 
conditions including hypertension, obesity, and stroke (Phillipson, 1993; Wright, Johns, 
Watt, Melville, & Sheldon, 1997). Given the health risks associated with OSA, early 
identification and treatment is essential. The most effective form of treatment for OSA is 
continuous positive airway pressure (CPAP). This technology delivers pressurized air to a 
mask that covers the nose which is attached to the face by head straps. The continuous 
positive pressure prevents the airway from collapsing during inhalation. The therapeutic 





nightly usage between 3.4-4.5 hours (Wright et al., 1997). In addition to the immediate 
reversal of apneic episodes and increased density of REM stage sleep, treatment with 
CPAP is associated with more distal benefits including a reduction in daytime 
somnolence, improved mood, and increased alertness (Engelman et al., 1999; Jenkinson, 
Davies, Mullins, & Stradling, 1999; Means et al., 2003; Schwartz, Kohler, & Karatinos, 
2005).   
Epidemiological research has estimated that more than 4% of adults suffer from 
sleep apnea syndrome (Young et al., 1993). The majority of this published literature, 
however, has examined the prevalence rates in age selected samples given the presence of 
sleep apnea has been observed more frequently in older adult men (Ancoli-Israel, Kripke, 
Mason, & Kaplan, 1985; Bixler, Vgontzas, Have, Tyson, & Kales, 1998). When 
considering obstructive sleep apnea more specifically, few studies have investigated its 
prevalence in the general population. One reason for this lack of research is that a formal 
diagnosis of OSA can only be established through an overnight polysomnography 
assessment. Punjabi (2008) conducted a literature review of available population-based 
studies on the prevalence of OSA and estimated the prevalence of OSA is approximately 
3 to 7% for adult men and 2 to 5% for adult women. One study that used overnight PSG 
to examine a general population sample of men (n = 741) aged 20-100 found OSA 
occurred in 3.3% of their sample with the highest prevalence (5%) occurring for ages 45-
64 (Bixler et al. 1998).  
Apneic events associated with OSA can occur during any stage of sleep but more 
commonly occur during REM stage sleep. REM stage sleep is characterized by an 





sporadic rapid eye movement, and muscle paralysis (Carskadon & Dement, 2000). 
During REM stage sleep the muscles of the upper airway become hypotonic which can 
lead to a partial or complete obstruction that disrupts the flow of air (Strollo & Rogers, 
1996; Youakim et al., 1998). The propensity of apneic episodes to occur during REM 
sleep in OSA results in REM stage sleep fragmentation and an overall decrease in the 
percentage of REM stage sleep (Strollo & Rogers, 1996).  
Sleep Disordered Breathing and PTSD 
Cross-sectional data suggest a strong association between sleep-disordered 
breathing and PTSD (Krakow et al., 2000; Krakow et al., 2001; Orr et al., 2010; Youakim 
et al., 1998). For example, an examination of 156 sexual assault survivors with PTSD 
found approximately 55% reported symptoms consistent with a positive screen for SDB 
(Krakow et al., 2000); however, in that study, the investigators did not confirm SDB 
through polysomnographic assessment. A similar rate (54%) was reported for a sample of 
patients with war-related PTSD who did undergo overnight polysomnography (Dagan, 
Lavie, Bleich, 1991). In this study 13 of the 24 patients exhibited a pattern of respiratory 
disturbance characteristic of SBD. A second study that utilized overnight 
polysomnography to detect SDB (Krakow et al., 2004) found a slightly lower prevalence 
(50%) rate in a sample of 78 fire evacuees seeking treatment for PTSD. A more recent 
study analyzed the records of 80 soldiers (89.6% men; mean age = 37.7 years) who 
recently returned from combat deployment and were diagnosed with PTSD (Orr et al., 
2010). Of the 80 soldiers, 58 underwent overnight polysomnography and 61% were 
subsequently diagnosed with obstructive sleep apnea. Finally, in an uncontrolled study 





(2001) found approximately 50% of the sample met diagnostic criteria for OSA. Taken 
together, these data support the notion that SDB and PTSD frequently co-occur, and that 
individuals with PTSD are at higher risk for SDB and OSA. Unfortunately, these studies 
are limited by small samples and varying methodologies. Further research is needed to 
provide a more accurate prevalence rate of these disorders among individuals with PTSD.  
Potential pathways linking SDB to PTSD. The relationship between SDB or 
OSA and PTSD has not been directly examined; however, similarities across several lines 
of research have led to hypotheses about mechanisms potentially underlying this 
relationship. The first of these hypotheses concerns REM stage sleep dysfunction as a 
mechanism explaining co-morbid OSA and PTSD. This hypothesis posits that disturbed 
sleep among individuals with PTSD involves altered REM sleep accrual or dysfunctional 
REM sleep processes (Ross et al., 1989). Given the strong association between apneic 
episodes and REM stage sleep dysfunction, the presence of OSA may be particularly 
relevant to the development or exacerbation of PTSD symptoms. Dysfunctional REM 
sleep mechanisms have been implicated as a possible pathway linking sleep dysfunction 
to PTSD, although this theory has not been subjected to empirical scrutiny (Ross et al., 
1994). Some evidence suggests individuals with PTSD experience lower percentages of 
REM stage sleep than do individuals without PTSD (Glaubman, Mikulincer, Porat, & 
Wasserman, 1990; Habukawa et al., 2003). Other studies have observed greater REM 
density and more rapid REM onset latency in individuals with PTSD (Mellman et al., 
1993; Ross et al., 1989), which may result from previous episodes of REM sleep 
dysfunction. Regardless, dysfunctional REM stage sleep has been observed in individuals 





REM stage sleep have been associated with a higher rate of reported nightmares and 
associated physiological arousal (Mellman et al., 1995; Ross et al., 1989; Ross et al., 
1994).   
Another potential pathway linking OSA to PTSD pertains to the possibility that 
similar maladaptive health behaviors are prevalent among individuals with OSA and 
individuals with PTSD. In particular, research has demonstrated strong associations 
between obesity and both PTSD and OSA. As previously mentioned, obesity has been 
associated with increased risk for OSA (Levitzky, 2008; Young et al., 1993), and it has 
also been linked to PTSD. For example, a nationally representative survey of 
approximately 13,000 individuals examined the association of obesity across mental 
disorders and found that PTSD was most strongly associated with obesity (Scott, McGee, 
Wells, Oakley-Browne, 2008). This association appears particularly pronounced among 
veterans. A strong association between PTSD and obesity was observed in a large sample 
of female veterans (n = 1259) such that the veterans who had screened positive for PTSD 
concurrently demonstrated higher body mass index (BMI) than veterans not screening 
positive (Dobie et al., 2004). Parallel findings were observed in a sample of male 
veterans with PTSD such that the rate of obesity in veterans (46.5%) exceeded the 
national average by 50% (Vieweg et al., 2006). Given the high rates of obesity found in 
samples of individuals with PTSD, and its associated risk for OSA; individuals with 
PTSD may be at greater risk to develop OSA due to poor health behaviors which lead to 
obesity.  
 Despite the lack of a more comprehensive understanding between OSA and 





conditions has led to an increase in empirical inquiry. More recent research in this area 
has examined whether or not successful treatment of OSA could result in amelioration of 
PTSD symptoms more generally. If such a relationship was observed between successful 
treatment of OSA and reduction in PTSD symptoms, those data might support the notion 
that OSA contributes to the persistence of PTSD. No published investigation has 
prospectively examined changes in PTSD symptoms following treatment for sleep-
disordered breathing, but several studies have examined this relationship retrospectively. 
For example, Krakow and colleagues (2000) examined existing hospital records of 23 
patients treated with CPAP for sleep-disordered breathing that also presented with co-
morbid nightmares or PTSD. Post-treatment follow-up of these individuals revealed that 
those patients that had maintained CPAP treatment reported a 93% improvement in sleep 
and daytime functioning compared to a 33% improvement for patients who had not 
complied with treatment. In addition, CPAP compliant patients reported an 85% 
improvement in nightmares and 75% improvement in PTSD symptoms compared with a 
10% and 45% worsening in symptoms respectively for the non-treatment compliant 
individuals. 
Similar results were reported in a single case evaluation of a 42-year male 
Vietnam veteran with co-morbid PTSD and OSA (Youakim et al., 1998). In this instance, 
the veteran was treated with CPAP for OSA and experienced immediate improvements in 
sleep quality and quantity and an overall decrease daytime sleepiness. At 4-month 
follow-up the veteran indicated considerable improvement in PTSD symptoms including 





diminished startle response, fewer re-experiencing symptoms. In addition the veteran 
reported decreased frequency of re-experiencing symptoms.  
Although not specific to PTSD, several studies were identified that examined 
changes in depressive symptoms following CPAP treatment for obstructive sleep apnea 
(Borak, Cieslicki, Koziej, Matuszewski, & Zielinkski; 1996; Engleman et al., 1999; 
Engleman, Cheshire, Deary, & Douglas, 1993; Means et al., 2003; Schwartz et al., 2005). 
For example, in a hospital sample (N = 50) newly diagnosed with OSA, the initiation of 
CPAP treatment was associated with a reduction in self-reported depressive symptoms 4-
6 weeks following treatment initiation (Schwartz et al., 2005). Similar findings were 
reported for a sample (n = 21) of patients diagnosed with OSA (Engleman et al. 1996) in 
which participants that “complied well” (n = 14) with CPAP treatment (i.e., > 
4.5hrs./night) reported a significant reduction in depression score compared to individuals 
(n = 7) utilizing their CPAP less. A third study identified examined 39 hospital 
outpatients diagnosed with OSA following clinical evaluation with overnight 
polysomnography. Results showed a statistically significant decrease in depressive 
symptoms for the overall sample 3-month post treatment initiation. Of note, CPAP 
compliance in this investigation was not found to be a significant predictor of change in 
depressive symptoms; however, the authors noted the analyses approached statistical 
significance. In the only study to implement a randomized placebo-controlled design, 
Engelman and colleagues (1999) prospectively monitored depression symptoms in 34 
patients presenting with mild OSA. Following random assignment to either CPAP or 
placebo CPAP, they found patients utilizing CPAP reported significantly reduced 





change in self-reported depressive symptoms following CPAP treatment for OSA (Borak 
et al., 1996). This study assessed depressive symptoms in 20 men diagnosed with severe 
OSA prior to CPAP treatment and again 3-months and 12-months following CPAP 
initiation. Unfortunately, this study does not provide information on CPAP utilization 
across the follow-up period, so it is unclear if the lack of change in depressive symptoms 
was associated with CPAP compliance/noncompliance, severity of OSA, or a 
combination of both factors. Given the lack of research examining the association 
between PTSD and OSA, in addition to the symptom overlap for PTSD and depression 
diagnoses, these studies provide more general support for the idea that successful 
treatment OSA may be associated with improvements in concurrent psychiatric 
functioning.  
Although it is difficult to draw conclusions from this small literature base, this 
research highlights the possibility of improvement in psychological symptoms following 
successful treatment of co-morbid sleep disorders. To further investigate this potential 
relationship, the current study prospectively monitored PTSD symptoms in veteran 
sample initiating CPAP treatment for obstructive sleep apnea.  
Hypotheses 
 The purpose of this study was to prospectively examine the associations between 
CPAP treatment for obstructive sleep apnea and change in posttraumatic stress symptoms 
in a sample of veterans. This study monitored change in posttraumatic stress symptoms, 
subjectively rated indices of sleep quality and sleep difficulties, and trauma related 
nightmares following OSA treatment implementation. The study design is quasi-





two pre-treatment observations and two post-treatment observations. A nonequivalent 
dependent variable was included, which allowed for the novel examination of CPAP 
treatment on PTSD symptoms and other aspects of sleep functioning in the absence of a 
true experimental design. In particular, the aims and corresponding hypotheses of the 
study were as follows: 
1. To examine whether participants who complied with CPAP treatment for OSA 
realized a significant change in their posttraumatic stress symptoms compared to 
pre-treatment severity.  
Hypothesis 1: We predicted that participants who were compliant 
(reporting an average of at least 4 hours/night over the post-treatment 
monitoring period) with CPAP treatment would report a statistically 
significant reduction in PTSD symptoms during post-treatment follow-
up compared to pretreatment symptom severity.   
2. To examine whether participants who complied with CPAP treatment for OSA 
realized a significant improvement across indices of sleep quality and sleep 
difficulties  
Hypothesis 2a. We predicted that participants who were compliant 
(reporting an average of at least 4 hours/night over the post-treatment 
monitoring period) with CPAP treatment would report a statistically 
significant increase in overall sleep quality during post-treatment 
follow-up compared to pretreatment symptom severity. 
Hypothesis 2b. We predicted that participants who were compliant 





monitoring period) with CPAP treatment would report a statistically 
significant decrease in PTSD-related sleep dysfunction during post-
treatment follow-up compared to pretreatment symptom severity. 
3. To examine whether participants who complied with CPAP treatment for OSA 
realized a significant improvement in nightmare-related distress compared to pre-
treatment report.  
Hypothesis 3. We predicted that participants who were compliant 
(reporting an average of at least 4 hours/night over the post-treatment 
monitoring period) with CPAP treatment would report a statistically 
significant decrease in nightmare-related distress during post-treatment 
follow-up compared to pretreatment symptom severity. 
4. To examine whether participants who complied with CPAP treatment for OSA 
realized a significant improvement in daytime sleepiness compared to pre-
treatment report.  
Hypothesis 4. We predicted that participants who were compliant 
(reporting an average of at least 4 hours/night over the post-treatment 
monitoring period) with CPAP treatment would report a statistically 
significant decrease in daytime sleepiness during post-treatment follow-
up compared to pretreatment symptom severity. 
Method 
Participants 
 Of the 489 veterans initially invited to participate, 70 were enrolled and 





participants were eligible for further participation (see Procedures for more detailed 
information); however, only 47 completed at least one post-treatment follow-up 
assessment. The final sample consisted of 47 veterans, who presented to the Neurology 
Sleep Clinic at the Memphis Veteran Affairs Medical Center (VAMC) and at a minimum 
completed the baseline assessment and one post-treatment assessment. The majority of 
the sample was male (n = 42; 89.4%) and ages ranged from 31 to 69 years old (M = 
53.53; SD = 10.27). A majority of the sample described themselves as either 
White/Caucasian (n = 23; 48.9%) or Black/African American (n = 22; 46.8%) with one 
individual (2.1%) selecting multiple racial descriptors and one (2.1%) declining to 
specify. Just over half the sample (55.3%; n = 26) reported being involved in a 
relationship with 24 participants currently married and two participants in a relationship 
with a member of the opposite sex. Of the remaining participants, seven (14.9%) reported 
they were currently single, 13 (27.7%) reported being divorced, and one participant 
(2.1%) was widowed. CPRS medical record review found 31.9% (n = 15) of participants 






Table 1   
Baseline Sample Demographics   





N 47 25 22   
Age - M (SD) 53.53 (10.27) 53.84 (11.19) 53.18 (9.38) t (45) = -.22  
Gender – (%)      
     Male  42 (89.4) 21 (84.0) 21 (95.5)  .00 
     Female 5 (10.6) 4 (16.0) 1 (4.5)  1.80 
Race/Ethnicity - (%)      
     White or Caucasian 23 (48.9) 14 (56.0) 9 (40.9)  1.07 
     Black or African American 22 (46.8) 10 (40.0) 12 (54.5)  .99 
     Other 2 (4.3) 1 (4.0) 1 (4.5)  .01 
Relationship Status - (%)      
     Single 7 (14.9) 3 (12.0) 4 (18.2)  .35 





Table 1  (continued)   
Baseline Sample Demographics 





     Not married – in relationship (opposite sex) 2 (4.3) 1 (4.0) 1 (4.5)  .01 
     Married 24 (51.1) 13 (52.0) 11 (50.0)  .02 
     Divorced 13 (27.7) 8 (32.0) 5 (22.7)  .50 
     Widowed 1 (2.1) 0 (0.0) 1 (4.5)  1.16 
BMI - M (SD) 33.58 (5.31) 33.91 (4.74) 33.20 (6.01) t (44) = -.45  
AHI - M (SD) 40.12 (28.36) 38.51 (29.17) 42.14 (27.95) t (43) = .42  
Active Medical Diagnoses - M (SD) 7.84 (4.19) 8.00 (4.40) 7.65 (4.02) t (43) = -.28  
CPRS Diagnosed PTSD – (%)  15 (31.9) 9 (36.0) 6 (27.3)  .18 






 Eligible veterans who consented to participate completed a battery of 
questionnaires that assessed various aspects of mental and physical health functioning 
including traumatic event exposure, PTSD symptom severity, aspects of sleep and sleep-
related dysfunction, nightmares, and daytime functioning. Participants also reported on 
their coping styles, physical health, and personality characteristics. A participant’s level 
of CPAP compliance was assessed using a self-report daily sleep diary that included 
specific assessment of nightly CPAP usage. Participants’ medical records were also 
reviewed to extract body mass index (BMI; as calculated in the Neurology Sleep Clinic 
polysomnographic report), active comorbid medical or psychiatric diagnoses, and 3-
month CPAP SmartCard data (as an objective index of CPAP compliance after 
approximately 3-months of use). For a complete list of measures administered at each 





Table 2  





Pre-treatment – 1  
Prior to CPAP* 
Post-treatment – 1 
2-weeks post 
CPAP 
Post-treatment – 2 
1-month post 
CPAP  
Demographics X    
The Life Events Checklist X    
PTSD Checklist – Stressor Specific X X X X 
Pittsburgh Sleep Quality Index   X X X X 
Epworth Sleepiness Scale X X X X 
Nightmare Distress Questionnaire X X X X 
Daily Sleep Diary (Compliance)   X X 
Short Form Health Survey 12 X X X X 
Brief COPE X    
Big Five Inventory  X X X X 






Measures of Trauma Exposure and Post-traumatic Stress Disorder.   
 The Life Events Checklist (LEC; Gray, Litz, Hsu, & Lombardo, 2004). The 
LEC is a 17-item self-report measure designed to screen for lifetime exposure to 
potentially traumatic events. For each item, the participant is instructed to indicate 
whether the event happened to them personally, if they witnessed the event, if they 
learned about the event, if they are unsure the item applies, or the item does not apply to 
them. For the purposes of this project, a brief follow-up assessment was conducted to 
obtain more information about the most salient traumatic experience identified to verify 
the trauma met Criterion A trauma exposure as specified in DSM-IV-TR (APA, 2000).  
 PTSD Checklist-Stressor - Specific Version (PCL; Weathers, Litz, Herman, 
Huska, & Keane, 1993). The PCL is a 17-item measure that directly corresponds to the 
DSM-IV-TR (APA, 2000) criteria for PTSD. The PCL utilizes a 5-point Likert scale 
ranging from 1 (“not at all”) to 5 (“extremely”) and instructs participants to respond to 
questions regarding the level of distress that was experienced related to each PTSD 
symptom over the past month. The stem question “The event you experienced was:” is 
specific to the PCL-S version and was pre-populated for all assessment time points 
based on the worst traumatic event description provided during the preliminary 
(baseline) trauma assessment. A full PTSD symptom severity score can be derived by 
totaling the responses from all 17-items (range: 17-85) and specific PTSD symptom 
subscale scores can be derived for the cluster B (“re-experiencing”), cluster C 
(“avoidance/numbing”), and cluster D (“hypeararousal”) as defined by DSM-IV-TR 
(APA, 2000). The PCL has demonstrated strong psychometric properties in other studies 





and is well-validated in veteran samples (Grieger, Kolkow, Spira, & Morse, 2007; Keen, 
Kutter, Niles, Krinsley, 2008; Pietrzak, Johnson, Goldstein, Malley, & Southwick, 
2009). Previous research has found the PCL demonstrated sound test-retest correlation 
coefficients of .88 after one week and .68 after two weeks (Ruggiero, Del Ben, Scotti, & 
Rabalais, 2003). For the purposes of this study a screening cut-off score of ≥ 25 was 
used to identify participants who are experiencing at least mild PTSD symptoms. This is 
the suggested cut-off score when screening for PTSD in a primary care sample of 
veterans (Prins, Kimerling, Yeager, & Magruder, 2010). For the purposes of this study, 
the PCL-S instructions were modified for the follow-up assessments, instructing 
participants to respond to questions in regard to their experience over the previous two 
weeks.  
Measures of Sleep, Sleep Disturbance, Nightmares, and Daytime Functioning 
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989). The PSQI is a 19-item self report measure designed to assess sleep quality 
and includes indices of sleep duration, sleep latency, and the frequency and severity of 
sleep difficulties. The PSQI utilizes a 4-point Likert-type scale ranging from 0 (“not 
during the past month”) to 3 (“three or more times a week”). The PSQI instructs 
participants to respond to questions retrospectively about their experience in the past 
month and to reply to the questions in a manner that is consistent with the majority of 
days in the previous month. The PSQI can be used to derive seven component scores 
(sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, 
use of sleep medications, and daytime dysfunction) which are summed together to yield a 





difficulties and lower sleep quality. Qualitatively, a Global Sleep Quality Index of 5 or 
greater indicates a “poor” sleeper (Buysse et al., 1998). The PSQI has demonstrated good 
test–retest reliability, validity, and internal homogeneity (Buysse et al., 1989). Using a 
cut-score of 5, the PSQI has demonstrated both high sensitivity (89.6%) and specificity 
(86.5%; kappa = 0.75) in distinguishing good from poor sleepers (Buysse et al., 1989). 
For this study, the PSQI instructions were modified for the follow-up assessments, 
instructing participants to respond to with reference to the previous two weeks.  
Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A; Germain, Hall, 
Krakow, Shear, Buysse, 2005). The PSQI-A consists of seven self-report items that 
assess the frequency of seven disruptive nocturnal behaviors (DNB) associated with 
PTSD. These seven items assess the frequency of hot flashes, general nervousness, 
memories or nightmares of trauma, anxiety or panic unrelated to trauma, nightmares 
unrelated to trauma, night terrors during sleep, and episodes of acting out dreams. The 
PSQI-A addendum is added to the PSQI’s original 19-item measure. The global PSQI-A 
score of 4 produced a sensitivity of 94% and a specificity of 82% for discriminating 
individuals with PTSD from those without PTSD. For the purposes of this study, the 
PSQI-A instructions were modified for the follow-up assessments, instructing 
participants to respond to questions in regard to their experience over the previous two 
weeks. 
 Epworth Sleepiness Scale (ESS; Johns, 1991). The ESS is an eight item self 
report questionnaire designed to provide a subjective estimation of daytime sleepiness. 
The ESS utilizes a 4-point Likert-type scale ranging from 0 (“would never doze”) to 3 





across eight common situations of daily living (e.g., “sitting and reading”, “watching 
TV”, “as a passenger in a car for an hour without a break”). A total ESS score (range: 
0-24) is calculated by summing the total of the eight items to derive an average sleep 
propensity score. A score greater than 10 is typically considered outside normal limits 
thus indicative of significant sleepiness (Johns, 1991). The ESS has demonstrated sound 
test-retest reliability in both medically healthy normal sleepers and patients treated for 
obstructive sleep apnea (Johns, 1992). The ESS has also been found to be sensitive to 
sleep-disordered breathing severity demonstrating a linear relationship with sleep apnea 
(Johns, 1993).  
 Nightmare Distress Questionnaire (NDQ; Belicki, 1992). The NDQ is a 13-
item self report measure designed to provide a measure of nightmare intensity. The scale 
employs a Likert-type scale format to assess the frequency of nightmare related 
emotional distress. The first 10 items are reversed scored and all 13 items provide a 
summed total score ranging from 13-55, higher scores indicating higher levels of 
nightmare related distress. Across four samples Belicki (1992) reported reliability 
estimates ranging from .83 to .88. For the purposes of this investigation the time period 
assessed was modified from “past year” to “past two weeks.” 
Health Measure 
 Short Form Health Survey 12 (SF-12; Ware, Kosinski, & Keller, 1996). The 
SF-12 is a 12-item self-report measure used to assess overall health functioning. The SF-
12 can be used to derive two subscales: the mental health component summary and the 
physical health component summary. Two week test-retest correlations of .89 and .76 





respectively (Ware et al., 1996). The SF-12 has been used in a wide range of populations 
and is considered a valid instrument. 
Coping  
 Brief COPE (Carver, 1997). The Brief COPE is a 28-item self-report measure 
used to examine an individual’s strategies of coping in response to stressful situations. 
The measure is divided into 14 subscales which include (self-distraction, active coping, 
denial, substance use, emotional support, instrumental support, behavioral 
disengagement, venting, positive reframing, planning, humor, acceptance, religion, and 
self-blame. The Brief COPE has been utilized in a range of populations including 
veterans with mental health concerns (Moore, Varra, Michael, & Simpson, 2010). 
Carver (1997) reported the internal reliabilities of the Brief COPE subscales to range 
from .50 (venting) to .90 (substance use). The Brief COPE was administered to 
participants during the baseline assessment.  
Treatment Compliance  
Daily Sleep Diary. The Daily Sleep Diary is a commonly used sleep measurement 
technique. The measure included in this study was modified specifically for this project to 
retrospectively assess both the characteristics of sleep and CPAP treatment compliance. For 
each post-treatment assessment, the participant was instructed to complete a daily log of their 
sleep habits including 1) time they got into bed the previous evening; 2) the time they got out 
of bed in the morning; 3) length of time they used their CPAP machine; 4) a subjective rating 
of overall sleep quality; and 5) any sleep medication use.  
Side Effects Questionnaire (SEQ; Kribbs et al., 1993). The SEQ is a 22-item self-





associated with CPAP use. Each side effect is rated on a scale from 0 (“not a problem”) to 3 
(“a serious problem”). The SEQ was administered at the final follow-up assessment (post-
treatment time point 2). The side effects scale was added to the active study protocol due to 
elevated rates of CPAP non-compliance. Thererfore only a subset of participants (n = 24) 
were adminstered this measure.  
Personality  
 The Big Five Inventory (BFI; John, Naumann, & Soto, 2008). The BFI is a 44-item 
self-report inventory designed to assess the Big Five personality dimensions of extraversion, 
agreeableness, conscientiousness, neuroticism, and openness. The measure asks participants 
to rate how much they agree with a series of short statements utilizing a 5-point Likert-type 
scale ranging from 1 (“Disagree Strongly”) to 5 (“Agree Strongly”). For the purposes of this 
study only the conscientiousness personality trait was measured. The purpose of the 
conscientiousness scale is to serve as a non-equivalent dependent variable that is not 
expected to change as a function of the CPAP treatment.  
Procedure 
 Recruitment. Potential study participants were identified through the 
computerized personalized record system (CPRS) as they were scheduled for an 
overnight sleep study in the Neurology Sleep Clinic at the Memphis Veterans Affairs 
Medical Center. Once identified, potential participants were screened through the 
information available in their CPRS medical record and Neurology Sleep Clinic initial 
consult. A participant was eligible for recruitment if they met the following criteria: 1) at 
least 18 years of age; 2) no previous history of treatment with CPAP for sleep breathing 





medical diagnosis (e.g., terminally ill) that could compromise their participation. 
Participants meeting these initial eligibility requirements (N = 489) were sent a letter 
explaining the purpose of the study and how the veteran may initiate participation in the 
study or how to opt out of the project. Approximately 10 days after sending the contact 
letter, if the participant had not initiated contact, the researcher followed up with potential 
participants by telephone to ensure receipt of the recruitment letter and answer any 
questions. Interested participants were scheduled for a baseline assessment prior to their 
overnight sleep study. Following the recruitment letter, participants were also recruited 
in-person at the Memphis VAMC. Potential participants were approached by research 
staff in the waiting room of the Neurology Sleep Clinic the evening of their overnight 
sleep study. Veterans were provided information about the research project and if 
interested, completed the baseline assessment prior to the start of their overnight sleep 
study.  
During the baseline assessment, the researcher explained project procedures, 
potential risks and benefits of participation, aspects of confidentiality, and provided the 
rationale for the HIPAA release. All study participants provided informed consent and 
HIPPA authorization if they chose to proceed with participation. In order to maintain 
confidentiality eligible veterans who consented to participate were assigned an 
alphanumeric participant identification number produced by a random number generator. 
Assessment. Assessment for current study consisted of three phases: a baseline 
screening assessment, a pretreatment follow-up phase, and a post-treatment follow-up 
phase. A total of 70 participants were recruited for the baseline assessment and each 





measures administered at each time point see Table 2). Participants were not 
compensated for completing the baseline assessment.  
The second phase of the study consisted of a pre-treatment assessment which 
occurred following the overnight sleep study, but prior to the receipt of the CPAP 
machine. A participant was deemed eligible for the pretreatment follow-up phase if: 1) 
they scored ≥ 25 on the baseline administration of the PCL-S and 2) were diagnosed with 
OSA from their overnight PSG examination. Eligible and interested participants were 
assessed prior to the receipt of their CPAP machine with the assessment measures 
reflecting the veterans’ functioning and symptom experience over the previous two week 
period. A total of 51 participants were eligible for the pretreatment phase; however, only 
27 (52.9%) participants completed this assessment phase. Of the remaining 24 
participants (47.1%), 18 were given their CPAP machine immediately following their 
overnight sleep study (thus were unable to complete the pretreatment follow-up phase), 
four participants were unable to be contacted for further participation, and two 
participants did not complete the pretreatment assessment prior to CPAP treatment 
initiation. Participants were compensated $10 for completing the pretreatment 
assessment. 
The third phase of the study consisted of two post-treatment follow-up 
assessments. A veteran was deemed eligible for the post-treatment follow-up phase if 
they met the following criteria: 1) completed a night the overnight sleep study; 2) were 
diagnosed with OSA; and 3) received a CPAP machine. Participants meeting these 
criteria were assessed two weeks following initiation of CPAP treatment (post-treatment 





treatment follow-up 2) Forty-five participants (95.7%) completed the 2 week post-
treatment follow-up and 44 participants (93.6%) completed the 4 week post-treatment 
follow-up. Participants were compensated $5 for completion of each post-treatment 
follow-up assessment. Figure 1 presents a flow chart of participant recruitment and 
completion across the three phases of assessment. All study procedures were approved 
through the university’s institutional review board (IRB) as well as the Memphis VAMC 
(IRB) and Research and Development committee. 
Data Analysis Plan 
 The following analyses evaluated the associations between CPAP compliance for 
obstructive sleep apnea and change in PTSD symptoms, subjectively rated sleep 
difficulties, daytime sleepiness, and nightmare distress after CPAP treatment initiation. 
The final study sample (N = 47) consisted of veterans who, at a minimum, completed 
the baseline assessment, had a PCL ≥ 25 at baseline, and completed at least one of the 
post-treatment assessments.  
  Prior to conducting the analyses we examined the distributional properties of all 
continuous variables. Using a criterion of 3.29 SD units from the mean (Tabachnick & 
Fidell, 2005), there were no outliers on any variable in the dataset. We examined 
whether the variables were skewed or kurtotic and found all variables demonstrated 





















Figure 1. Flow chart of participant recruitment 
Note. Of the 47 veterans eligible for pretreatment assessment, 18 received CPAP immediately following the overnight 
polysomnography study, thus were unable to complete the pretreatment assessment.
489 Veterans invited to participate  
19 Veterans ineligible 
 10 did not meet PCL inclusion criterion 
 6 did not receive sleep apnea diagnosis 
 3 did not pick-up their CPAP machine 
 
4 Veterans could not be contacted after baseline 
 
 
51 Veterans eligible for pretreatment follow-up 
 
27 Veterans completed the Pretreatment (Time 2)* 
45 Veterans completed the Post-treatment 1 (Time 3) 
44 Veterans completed the Post-treatment 2 (Time 4) 
 






 Baseline descriptive characteristics of the overall sample will be presented first, 
including the demographic information (gender, age, ethnicity, relationship status) as 
well as the means and standard deviations for the primary outcome variables (PTSD 
symptom severity, overall sleep quality, PTSD-related sleep disruption, nightmare 
distress, and daytime sleepiness). Baseline and pre-treatment descriptive characteristics 
were compared between participants who were CPAP-compliant and those who were 
non-compliant. We conducted T-tests and chi square analyses to assess any significant 
differences between these groups prior to CPAP treatment initiation. Using independent 
samples t-test, we compared the types of coping strategies used by individuals who were 
CPAP complaints compared to strategies utilized by participants who were not CPAP-
compliant.  Finally, we compared participants who were CPAP-compliant and non-
compliant on the rate of endorsement of different adverse side effects associated with 
CPAP treatment. 
 The primary study analyses examined whether or not there was a statistically 
significant difference between CPAP-compliant and non-compliant participants on self-
reported PTSD symptom severity and indices of sleep disturbance at the follow-up time 
points. Prior to testing the mixed models, relations between sample characteristics 
(compliance status, BMI, and demographic variables) and the primary outcome 
variables (PCL-S total score, PSQI Global Severity Index, PSQI-PTSD Addendum 
score, NDS total score, and ESS total score) were explored using Pearson correlation 
statistics. Next, a series of mixed-model repeated measures analyses were conducted to 
compare CPAP-compliant and non-compliant participants on each of the primary 





known hierarchical linear models or multilevel models) provide a flexible framework for 
repeated measures analyses. Compared to traditional repeated measures analysis of 
variance (ANOVA), mixed-effect models utilize all available data for each participant to 
better accommodate for missing data (Gueorguieva & Krystal, 2004). For each model 
tested, one of the primary outcome variables served as the dependent variable. 
Demographic variables (i.e., gender, BMI, age, ethnicity, and relationship status) were 
included as covariates in a model if they were found to be correlated at the p < .10 level 
with group status (treatment compliant or non-compliant) or the respective primary 
outcome variable of the model.   
 Planned post-hoc comparisons were conducted for any statistically significant 
model effect or significant interaction. For all follow-up pairwise comparisons, 
precautions were taken to adjust for the possibility of detecting a false positive (Type-I 
error) significance level. We used the Bonferonni-Holm adjustment (Holm, 1979), to 
adjust the acceptable α-level based on the number of independent analyses conducted on 
our dataset (6). The Bonferroni-Holm procedure is adapted from the traditional 
Bonferroni correction, which modifies the acceptable alpha (α) level based on the 
number of comparisons being conducted. The traditional Bonferroni correction 
calculates adjusted α as: α/k (where k = number of comparisons) to be applied to all 
comparisons. This approach has been criticized as overly conservative and has the 
tendency to reduce power significantly (Holm, 1979). Given the small sample size of the 
current dataset, the modified Bonferroni-Holm adjustment was selected for its ability to 
increase power while still correcting for the possibility of familywise Type-I error. The 





1. Order the p-values from lowest to highest [p(1), p(2), … p(k)] for all 
comparisons 
2. Compare p(1) to α/k (where k = number of comparisons), if p(1) > α/k, then 
reject null hypothesis 1.  
3. Next, compare p(2) to α/(k-1), if p(2) > α/k-1, then reject null hypothesis 2. 
4. Evaluate all comparisons to confirm or reject the null hypothesis.  
The main study hypotheses had a maximum of six comparisons based on the four time 
points evaluated. Using the standard p > .05 statistical significance level as the starting 
α, Table 3 presents the adjusted p-values that will be applied to each comparison using 
the Bonferroni-Holm adjustment.  
As previously mentioned, this study included a non-equivalent dependent variable 
as an additional measure of control in order to reduce threats to internal validity that are 
associated with quasi-experimental designs (Coryn & Hobson, 2011). A non-equivalent 
dependent variable serves as a control variable that is similar to the primary dependent 
variables and is theoretically affected in the same way by threats inherent to a single 
group pretest-posttest design, but different enough from the primary variables that it will 
not be affected by treatment. Using the mixed-model repeated measures analyses 
described above, we examined whether participants who were compliant with CPAP 
treatment experienced change self-rated level of conscientiousness (the non-equivalent 





Table 3  
Adjusted α-level Based on Bonferroni-Holm Adjustment for Pairwise Comparisons 
 
Ordered comparison (c) 
Bonferroni-Holm 
equation 
α = .05/(k – c +1) 
 
Adjusted α-level 
1 α = .05/(k – 1 +1) .008 
2 α = .05/(k – 2 +1) .01 
3 α = .05/(k – 3 +1) .013 
4 α = .05/(k – 4 +1) .02 
5 α = .05/(k – 5 +1) .025 
6 α = .05/(k – 6 +1) .05 
Note. k = total number of comparisons (6). c = Ordered comparison based on p-value 







Prior to completing the PCL-S, all participants (N = 47) identified at least one 
potentially traumatic event using the Life Events Checklist. The most commonly reported 
“worst” events were categorized as “combat or exposure to war-zone” (48.9%) and 
“sudden, violent death” (10.6%). Other frequently endorsed “worst” events included “life 
threatening illness or injury” (6.4%), “transportation accident” (6.4%), “physical assault” 
(6.4%), and “exposure to toxic substances” (4.3%). At the baseline assessment the overall 
sample had a mean PCL-S score of 56.83 (SD = 15.33). For individuals that completed 
the pretreatment assessment (n = 28), the mean PCL-S score was 54.36 (SD = 14.09).   
Baseline and pretreatment ratings were examined for measures of overall sleep 
quality, PTSD-related sleep disturbance, nightmare distress, and daytime sleepiness. As a 
whole, participants in the sample were considered poor sleepers (based on prior research, 
which has suggested a cut score of 5 as the threshold for poor sleep), with a mean Global 
Severity Index score of 14.30 (SD = 3.54) at baseline and 14.17 (SD = 3.12) at 
pretreatment. Participants reported moderate levels of PTSD-related sleep dysfunction, 
with means of 9.00 (SD = 5.25) and 9.64 (SD = 5.24) at baseline and pretreatment 
respectively. The sample mean for nightmare-related distress was not in the elevated 
range prior to CPAP treatment initiation, with mean severity scores of 31.39 (SD = 9.88) 
at baseline and 29.54 (SD = 9.00) at pretreatment. The sample also an elevated level of 
daytime sleepiness with mean severity scores of 10.52 (SD = 6.04) at baseline and 12.40 
(SD = 5.93) at pretreatment Table 4 presents baseline and pretreatment descriptive 





PSQI-PTSD Addendum scores, NDS total scores, and ESS total scores) separately for 
CPAP-compliant participants and non-compliant participants. There were no statistically 
significant baseline or pretreatment differences between CPAP-compliant and non-
compliant participants on any of the primary outcome variables.  
In addition to the self-report questionnaires administered by study personnel, 
participant’s medical records were reviewed to obtain two additional physical health 
indicators, body mass index (BMI) and comorbid health conditions (total number of 
clinician-diagnosed physical health conditions). Participant’s BMI was recorded as part 
of their overnight sleep study at the Neurology Sleep Clinic. The Centers for Disease 
Control and Prevention (2011) classifies BMIs of <18.5 as “underweight,” 18.5 to 24.9 as 
“normal,” 25.0 – 29.9 as “overweight,” and > 30.0 as “obese.” Review of medical records 
revealed the sample mean fell in the “obese” range at 33.59 (SD = 5.31). Twelve 
participants (25.5%) were classified as “overweight” and 35 participants (74.5%) were 
considered “obese.” There was not a statistically significant difference in BMI for CPAP-
compliant and non-compliant participants. With respect to comorbid health conditions, 
the mean number of active diagnoses (excluding mental health conditions) for the full 
sample was 7.84 (SD = 4.19). There was not a statistically significant difference in the 
number of active physical health conditions for CPAP-compliant and non-compliant 
participants and this health index was not significantly correlated with any of the primary 





Table 4  
Baseline and Pre-treatment Descriptives across Time on PTSD Symptoms, Indices of Sleep, and Nightmare Distress compared 
by CPAP Compliance Status 
 CPAP-compliant (n = 25) 
M (SD) 




PCL-S Total Score (PCL-S)    
     Baseline PCL-S 56.13 (15.64) 57.59 (15.31) t (44) = .32 
     Pretreatment 1 PCL-S  54.13 (14.99) 54.62 (13.57) t (26) = .09 
PSQI Global Severity Index (GSI)    
     Baseline GSI 13.76 (3. 81) 14.95 (3.15) t (44) = 1.14 
     Pretreatment 1 GSI  14.25 (3.26) 14.08 (3.07) t (27) = -.15 
PSQI-PTSD Addendum (PSQI-PTSD)    
     Baseline PSQI-PTSD 8.43 (5.10) 9.81 (5.50) t (37) = .80 
     Pretreatment 1 PSQI-PTSD  9.43 (5.76) 10.00 (4.54) t (20) = .24 
*p ≤ .05. **p ≤ .01.   (table continues) 





Table 4 (continued) 
Baseline and Pre-treatment Descriptives across Time on PTSD Symptoms, Indices of Sleep, and Nightmare Distress compared 
by CPAP Compliance Status 
 CPAP-compliant (n = 25) 
M (SD) 




Nightmare Distress Scale (NDS)    
     Baseline NDS 29.73 (9.17) 33.32 (10.56) t (39) = 1.17 
     Pretreatment 1 NDS  28.15 (9.13) 30.92 (9.01) t (24) =.78 
Epworth Sleepiness Scale (ESS)    
     Baseline EES 9.25 (6.16) 12.05 (5.67) t (42) = 1.56 
     Pretreatment 1 EES  12.91 (6.20) 11.76 (5.78) t (27) = -.51 
*p ≤ .05. **p ≤ .01.    
    





The apnea-hypopnea index (AHI) is an objective measure of OSA severity that 
calculates the quantity of respiratory pauses (≥ 10 seconds in duration) during sleep per 
hour. According to recommendations from the American Academy of Sleep Medicine 
(Ruehland et al., 2009), AHI values between 5-15/hr are categorized a “mild OSA,” 
values between 15-30/hr as “moderate OSA,” and values >30/hr as “severe OSA.” 
Results from the Neurology Sleep Clinic’s sleep study report indicated 55.3% of the 
current sample was rated as having severe OSA, 14.9% as moderate, and 25.5% as mild. 
There was not a statistically significant difference in OSA severity between CPAP-
compliant and non-compliant participants and AHI was not significantly correlated with 
any of the primary outcome variables examined.  
 CPAP compliance. Subjectively reported CPAP utilization resulted in 27 
participants being classified as CPAP-compliant, averaging 6.19 (SD = 1.50) hours per 
night. The CPAP non-compliant group (n = 20) reported an average nightly usage of 1.11 
(1.30) hours. A measure of objective CPAP compliance (retrieved from each veteran’s 
CPAP “SmartCard,” an electronic device embedded in the CPAP equipment) was 
retrieved through chart review following the 3-month follow-up visit with the Neurology 
Sleep Clinic. Of the 47 total participants, SmartCard data was available for 23 
participants. Although a direct comparison of CPAP utilization was not possible due to 
the different follow-up periods for the current study and the Neurology Sleep Clinic (1-
month and 3-months respectively), the downloaded SmartCard data yielded a total days 
of use index. We compared the self-reported total day CPAP usage to the SmartCard total 
day usage and found SmartCard usage (total days used 3-months) was less than self-





SmartCard indicated a total of 13 days of usage for one and 9 days of usage for the other. 
We recalculated average nightly CPAP usage based on SmartCard indicated total days 
used and average self-reported nightly use. For both participants, CPAP usage fell below 
the cut-off ( ≥ 4) for treatment compliance, thus were reclassified as CPAP non-
compliant. The final sample included 25 participants considered CPAP-compliant and 22 
participants considered non-compliant.  
Cross-sectional Comparisons by CPAP Compliance Status  
Coping Strategies. Using independent samples t-tests, we compared the coping 
strategies utilized by participants who were CPAP-compliant compared to participants 
who were CPAP non-compliant. Of the 14 strategies measured by the Brief Cope 
(Carver, 1997), differences emerged across two scales. Participants who were not CPAP-
compliant reported using both “instrumental support” and “venting” significantly more 
compared with participants who were CPAP-compliant (Table 5). No other statistically 
significant group differences emerged for coping strategy utilization. 
Side Effects of CPAP. The side effects associated with CPAP treatment were 
measured at the four week follow-up time point. Using independent samples t-tests we 
compared the side effects of CPAP endorsed by participants who were CPAP-compliant 
compared with those who were non-compliant. Out of 21 side effects measured, results 
found non-compliant participants reported significantly more problems associated with 
CPAP mask irritation and CPAP-related sleep disturbance including more disturbed 
sleep, more restlessness, and poorer sleep (Table 6).  No statistically significant group 





Table 5  
Comparison of Coping Strategies by CPAP Compliance Status 
 CPAP-compliant (n = 14) 
M (SD) 




Coping Strategy    
     Self-distraction 5.29 (1.49) 5.15 (2.08) t (25) = -.19 
     Active coping 4.79 (1.76) 5.77 (1.74) t (25) = 1.46 
     Denial 5.00 (2.18) 4.31 (1.84) t (25) = -.89 
     Substance use 3.54 (2.30) 3.54 (1.98) t (25) = -00 
     Use of emotional support 3.57 (2.03) 5.08 (1.98) t (25) = 1.95
†
 
     Use of instrumental support 3.21 (1.48) 5.69 (1.98) t (25) = 3.76** 
     Behavioral disengagement 3.29 (1.48) 4.15 (2.11) t (25) = 1.26 
     Venting 4.21 (1.48) 5.77 (2.01) t (25) = 2.31* 
     Positive reframing 4.71 (1.68) 5.15 (1.68) t (25) = .68 
     Planning 5.07 (1.86) 5.23 (1.48) t (25) = .25 
†





Table 5 (continued)    
Comparison of Coping Strategies by CPAP Compliance Status 
 CPAP-compliant (n = 14) 
M (SD) 




     Humor 3.57 (1.87) 3.77 (2.49) t (25) = .24 
     Acceptance 5.29 (1.98) 6.38 (1.50) t (25) = 1.62 
     Religion 5.64 (1.95) 6.15 (2.27) t (25) = .63 
     Self-blame 4.57 (2.28) 5.38 (1.61) t (25) = 1.06 
†














Comparison of CPAP Side Effects by CPAP Compliance Status 
 
Side Effects 
CPAP-compliant (n = 15) 
M (SD) 




     CPAP is too inconvenient to use 1.00 (1.13) 1.56 (.88) t (22) = 1.26 
     The CPAP mark irritates my face .87 (.99) 1.75 (.71) t (21) = 2.23* 
     I can’t sleep because of the noise CPAP makes   .31 (.63) .89 (1.05) t (20) = 1.62 
     My eyes are irritated by CPAP .67 (.90) .78 (1.09) t (22) = .27 
     The CPAP mask makes me claustrophobic .53 (.92) 1.11 (.93) t (22) = 1.49 
     My ears are irritated by the CPAP machine
a 
.13 (.35) .56 (.88) t (22) = 1.67 
     I have chest pains when I use CPAP .13 (.35) .11 (.33) t (22) = -.15 
     I am embarrassed to use my CPAP .33 (.62) .44 (1.01) t (22) = .34 
     My nose bleeds when I use CPAP .27 (.46) .22 (67) t (22) = -.19 
     I have difficulty operating the CPAP machine .13 (.35) .11 (.33) t (22) = -.15 
     The CPAP makes the bridge of my nose hurt 1.20 (1.21) .78 (1.09) t (22) = -.86 
†





Table 6 (continued)    
Comparison of CPAP Side Effects by CPAP Compliance Status 
 
Side Effects 
CPAP-compliant (n = 15) 
M (SD) 




     I have trouble putting on the CPAP mask .20 (.56). .22 (.44) t (22) = .10 
     CPAP disturbs my sleep .47 (.83) 1.89 (.93) t (22) = 3.88** 
     CPAP gives me headaches .20 (.56) .11 (33) t (22) = -.43 
     CPAP results in less intimacy with my bed  
     partner 
.47 (.74) .25 (.46) t (21) = -.75 
     CPAP makes my nose stuffy or dry
a 
.47 (.64) 1.11 (1.27) t (22) = 1.66 
     I toss and turn more with CPAP .58 (.99) 1.67 (1.12) t (22) = 2.34* 
     I sleep poorly with CPAP .80 (1.15) 1.78 (.97) t (22) = 2.14* 
     My bed partner sleeps worse when I use  
     CPAP
a 
.29 (61) .63 (1.19) t (22) =.89 
     I sleep worse when I use CPAP .71 (1.14) 1.57 (1.27) t (22) = 1.57 
Note. 
a 
Levene’s Test for Equality of Variances = p < .05, thus equal variances not assumed.  
†





Mixed-model Repeated Measures Analyses 
Prior to testing the mixed models, relations between compliance status and 
demographic variables and the primary outcome variables (PCL-S total score, PSQI 
Global Severity Index total, PSQI-PTSD Addendum score, NDS total score, and ESS 
total score) were explored using Pearson correlation statistics. Factors correlated at the p 
< .10 level with compliance status or the primary outcome variables were included as 
covariates in their respective models. Correlation analyses are presented in Table 7. For 
the purposes of the current analyses, relationship status was recoded into a dichotomous 
variable that reflected being in a relationship or not. This was necessary given that some 
categories of relationship status had too few participants to allow for post-hoc 
comparisons if found to be significant. The recoded relationship status variable resulted 






Table 7  
Correlation Matrix for Demographic Variables and Primary Outcome Variables 
Variables 1 2 3 4 5 6 
Sample Characteristics       
1. Age ___      
2. Gender .05 ___     
3. Ethnicity .02 .15 ___    
4. Relationship status .11 -.38** -.17 ___   











6. Treatment compliance status .03 .19 -.14 .10 .07
a 
___ 

































































































































































Table 7 (continued) 
Correlation Matrix for Demographic Variables and Primary Outcome Variables 
Variables 1 2 3 4 5 6 



















































































































































































Note. PCL-S total = PTSD Checklist total score; PSQI global = Pittsburgh Sleep Quality 
Index Global Severity Index; PSQI-PTSD = Pittsburgh Sleep Quality Index PTSD 
Addendum total score; NDS total = Nightmare Distress Scale total score; ESS total = 
Epworth Sleepiness Scale total score. 
a
n = 46. 
b
n = 45. 
c
n = 44. 
d
n = 43. 
e
n = 42. 
f
n = 41. 
g
n = 40. 
h
n = 39. 
i
n = 38. 
j
n = 37.  
k




n = 26.  
n
n = 20 
o
 n = 28. 
†





Hypothesis 1. A 2 (group) x 4 (time) mixed-model repeated measures analysis 
was conducted to compare participants who were CPAP-compliant to those who were 
non-compliant on PTSD symptom severity. BMI was included as a covariate in this 
model given the significant negative correlation with baseline PCL-S total score. The 
results of this analysis did not show any statistically significant main effects (time, CPAP 
compliance, or BMI); however, analyses did find a statistically significant compliance 
status x time interaction (F(3, 102.15) = 5.66. p = .001). Follow-up Bonferonni-Holm 
corrected pairwise comparisons (Table 8) revealed that CPAP-compliant participants 
reported a statistically significant linear reduction in PTSD symptoms from pre to post-
treatment, whereas non-compliant participants did not report a statistically significant 
reduction from pre to post-treatment (Figure 2). For CPAP-compliant participants, the 
estimated marginal means (EMM) for PCL score at the baseline (EMM = 56.14) and 
pretreatment (EMM = 55.65) time points were significantly higher than the post-treatment 
1 (EMM = 46.73) and post-treatment 2 (EMM = 47.03) time points. Non-compliant 
participants reported a statistically significant reduction in PTSD symptoms from 
baseline (EMM = 57.59) to pretreatment (EMM = 52.07), indicating a significant 
reduction in PTSD symptoms prior to the treatment implementation. Further examination 
of this decrease in PTSD symptoms from baseline to pretreatment revealed 5 out of the 
13 non-compliant participants that completed pretreatment follow-up reported ≥ 9 point 
decreases in symptoms from baseline to pretreatment. Of note, there was not a 
statistically significant difference from baseline to pretreatment estimated marginal 
means for the CPAP-compliant group. The CPAP-compliant and non-compliant groups 





and standard deviations for each group across the four time points and Bonferonni-Holm 
corrected pairwise comparisons are presented in Table 9. 
A series of exploratory 2 (group) x 4 (time) mixed-model repeated measures 
analyses were conducted to compare participants who were CPAP-compliant to those 
who were non-compliant across the three DSM-IV-TR PTSD symptom domains 
(reexperiencing, avoidance/numbing, and hyperarousal). These analyses failed to find 
statistically significant main effects or significant interactions for reexperiencing (Figure 
3) and avoidance/numbing (Figure 4) symptom domains. A trend level compliance status 
x time interaction emerged for the hyperarousal symptom domain (F(3, 105.11) = 2.40. p 
= .072). Despite this trend level finding, follow-up Bonferonni-Holm corrected pairwise 
comparisons did not find a significant change in hyperarousal symptoms for either group 
(CPAP-compliant or non-compliant) from pre-to-post treatment (Figure 5). Of note, when 
we compared the estimated marginal means for CPAP-compliant and non-compliant 
participants at each time point, we found a statistically significant difference at the 
pretreatment time point such that non-compliant participants reported significantly more 






Figure 2.  Change over time in PTSD symptoms for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  
































Figure 3.  Change over time in re-experiencing symptoms for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  














































Figure 4.  Change over time in avoidance/numbing symptoms for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  













































Figure 5.  Change over time in hyperarousal symptoms for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  










































Two additional exploratory 2 (group) x 4 (time) mixed-model repeated measures 
analyses were tested that avoidance and numbing symptom domains separately. Analyses 
revealed a significant compliance status X time interaction for avoidance symptoms (F(3, 
107.47) = 2.96. p = .036). Follow-up Bonferonni-Holm corrected pairwise comparisons 
revealed that participants who were not compliant with CPAP treatment reported a 
statistically significant reduction in avoidance symptoms from the baseline (EMM = 7.93) 
and pretreatment (EMM = 7.80) time points to post-treatment 1 (EMM = 6.06) time point 
and between baseline and post-treatment 2 (EMM = 5.92) time points. CPAP-compliant 
participants did not report a statistically significant change from pre-to-post treatment. 
When we compared the estimated marginal means for CPAP-compliant and non-
compliant participants at each time point, we found a statistically significant difference at 
the baseline and pretreatment time points such that non-compliant participants reported 
significantly more avoidance symptoms compared to CPAP-compliant participants. No 
statistically significant main effects or interactions emerged for the model testing 
numbing symptoms. 
Hypothesis 2a. A 2 (group) x 4 (time) mixed-model repeated measures analysis 
was conducted to compare CPAP-compliant and non-compliant participants on overall 
sleep quality as measured by the PSQI Global Severity Index. Analyses revealed a 
statistically significant compliance status x time interaction (F(3, 101.59) = 5.65. p = 
.001). Follow-up Bonferonni-Holm corrected pairwise comparisons revealed that both 
CPAP-compliant and non-compliant participants reported a statistically significant 
improvement overall sleep quality from pre to post-treatment (Figure 6). For CPAP-





and pretreatment (EMM = 13.81) time points were significantly higher than the post-
treatment 1 (EMM = 9.60) and post-treatment 2 (EMM = 10.56) time points. There was 
not a statistically significant difference between baseline and pretreatment estimated 
means for this group. For CPAP non-compliant veterans, the baseline time point (EMM 
= 15.07) was significantly different from the post-treatment 2 (EMM = 12.13) time 
point; however, there was not a statistically significant difference between the baseline 
and post-treatment 1 (EMM = 13.15) time point or the pretreatment time point (EMM = 
13.86) and either of the post-treatment time points (Table 9). Analyses also revealed a 
statistically significant main effect for time (F(3, 101.59) = 13.12, p < .001) such that the 
full sample showed improvement in overall sleep quality across time. Means and 










Figure 6. Change over time in overall sleep quality for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  































Hypothesis 2b. A separate 2 (group) x 4 (time) mixed-model repeated measures 
analysis was conducted on PTSD-related sleep dysfunction as measured by the PSQI-
PTSD Addendum. Ethnicity was included as a covariate in this model given the trend 
level positive association with post-treatment 1 PSQI-PTSD total score (r = .32; p < .10) 
and post-treatment 2 PSQI-PTSD total score (r = .29; p < .10). Analyses revealed 
statistically significant main effects for time (F(3, 83.31) = 3.91, p = .012) such that the 
full sample reported a mean reduction in PTSD-related sleep disruption from pre-to-post 
treatment follow-up. Follow-up Bonferonni-Holm corrected pairwise comparisons (Table 
9) showed a statistically significant reduction in reported PTSD-related sleep disruption 
from the baseline (EMM = 9.00) and pretreatment (EMM = 8.58) time points to the post-
treatment 1 (EMM = 6.93) time point. There was not a statistically significant difference 
between any other time points. No statistically significant main effects emerged for 
CPAP compliance status or ethnicity.   
Hypothesis 3. A 2 (group) x 4 (time) mixed-model repeated measures analysis 
was conducted to compare CPAP-compliant and non-compliant participants on nightmare 
distress as measured by the Nightmare Distress Scale. Both BMI and relationship status 
were included as a covariates in this model given significant associations with NDS total 
score. Mixed model analyses revealed a statistically significant main effect for time (F(3, 
105.08) = 3.91, p = .011) such that the overall sample reported a linear increase in 
nightmare-related distress across time (see Figure 7). Follow-up Bonferonni-Holm 
corrected pairwise comparisons revealed a statistically significant increase in reported 
nightmare-related distress from the baseline (EMM = 28.03) time point to the post-





post-hoc comparison also revealed a statistically significant increase in nightmare distress 
from the baseline to pretreatment (EMM = 29.81) time point and no statistically 
significant difference between the pretreatment time point and either post-treatment 
follow-up time point (Table 9).   
Hypothesis 4. A 2 (group) x 4 (time) mixed-model repeated measures analysis 
was conducted to compare participants who were CPAP-compliant to those who were 
non-compliant on daytime sleepiness as measured by the Epworth Sleepiness Scale 
(Figure 8). Analyses failed to find any statistically significant main effects; however, 
there was a statistically significant compliance status x time interaction (F(3, 100.87 = 
3.60, p = .016). Follow-up Bonferonni-Holm corrected pairwise comparisons revealed a 
statistically significant increase in reported daytime sleepiness from baseline (EMM = 
8.85) to the pretreatment follow-up (EMM = 11.53) for the CPAP-compliant group. This 
difference was not observed for CPAP non-compliant participants. There were no other 


















Figure 7.  Change in nightmare distress over time for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 24, and 
post-treatment 2, n = 25. Sample sizes for the CPAP non-compliant group were: baseline, n = 22, pre-treatment, n = 13, post-
treatment 1, n = 21, and post-treatment 2, n = 19.  































Figure 8.  Change over time in daytime sleepiness for CPAP-compliant and non-compliant participants. 
Note. Sample sizes for the CPAP-compliant group were: baseline, n = 24, pre-treatment, n = 14, post-treatment 1, n = 23, and 
post-treatment 2, n = 24. Sample sizes for the CPAP non-compliant group were: baseline, n = 20, pre-treatment, n = 13, post-
treatment 1, n = 20, and post-treatment 2, n = 18.  


























Non-equivalent Dependent Variable. A 2 (group) x 4 (time) mixed-model 
repeated measures analysis was conducted to compare participants who were CPAP-
compliant to those who were non-compliant on the non-equivalent dependent variable 
conscientiousness as measured by the Big Five Inventory conscientiousness subscale. 
Age and relationship status were included as covariates in the model given the trend level 
positive associations with conscientiousness (Table 5). Analyses revealed a statistically 
significant main effect for compliance status (F(1, 44.32) = 4.31, p = .044); however, 
follow-up independent samples t-tests did not find a statistically significant difference 
between CPAP-compliant and non-compliant participants on self-reported 
conscientiousness at any of the four time points. No other statistically significant main 
effects or interactions emerged from the model. These findings suggest there was not a 
significant change in self-reported conscientiousness over time for either the CPAP-





Table 8  
Mean Scores across Time for the Primary Outcome Variables by Group Status 
Outcome variable T1 T2 T3 T4 Within-subjects effect size (d) 
   Group status M (SD) M (SD) M (SD) M (SD) d1 d2 d3 d4 
PCL-S total score         
   CPAP-compliant 56.13 (15.65) 54.62 (13.57) 46.83 (15.73) 47.16 (15.40) .96 .96 .70 .68 
   CPAP non-compliant 57.59 (15.31) 54.62 (13.57) 55.33 (14.42) 53.53 (13.79) .40 .21 -.08 .15 
PSQI Global Severity Index         
   CPAP-compliant 13.76 (3.81) 14.25 (3.26) 9.63 (3.72) 10.56 (4.52) 1.17 .75 1.52 .92 
   CPAP non-compliant 14.95 (3.15) 14.08 (3.07) 13.20 (4.27) 12.29 (3.82) .70 1.06 .51 .75 
PSQI-PTSD Addendum         
   CPAP-compliant 8.43 (5.11) 9.43 (5.76) 6.59 (5.35) 6.73 (5.24) .40 .38 .81 .82 
   CPAP non-compliant 9.81 (5.50) 10.00 (5.54) 8.20 (5.58) 8.57 (5.58) .59 .42 1.45 .67 






Table 8 (continued) 
Mean Scores across Time for the Primary Outcome Variables by Group Status 
Outcome variable T1 T2 T3 T4 Within-subjects effect size (d) 
   Group status M (SD) M (SD) M (SD) M (SD) d1 d2 d3 d4 
Nightmare Distress Scale         
   CPAP-compliant 29.73 (9.17) 28.15 (9.13) 28.32 (8.00) 27.00 (9.58) .26 .35 -.03 .18 
   CPAP non-compliant 33.32 (10.56) 30.92 (9.01) 31.11 (11.68) 29.78 (9.23) .33 .60 -.03 .23 
Epworth Sleepiness Scale          
   CPAP-compliant 9.25 (6.16) 12.91 (6.20) 9.59 (6.22) 9.33 (5.71) -.07 -.02 1.05 2.13 
   CPAP non-compliant 12.05 (5.67) 11.77 (5.77) 11.50 (5.68) 11.28 (4.74) .24 .16 .10 .15 
Note. The within-subjects Effect size was calculated using Morris and DeShon’s (2002) equation 8, which corrects for the 
dependence between repeated measure means. Baseline (T1) sample sizes: CPAP-compliant (n = 25) and CPAP non-
compliant (n = 22). Pretreatment 1 (T2) sample sizes: CPAP-compliant (n = 15) and CPAP non-compliant (n = 13). Post-
treatment 1 (T3) sample sizes: CPAP-compliant (n = 24) and CPAP non-compliant (n = 21). Post-treatment 2 (T4) sample 
sizes: CPAP-compliant (n = 25) and CPAP non-compliant (n = 19). d1 = T1 & T3 within-subjects effect size; d2  = T1 & T4 





Table 9  
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by 
Group Status 
Outcome variable 











PCL-S total score      
   CPAP-compliant 56.14 (2.97) 55.65 (3.15) 46.73 (2.97) 47.03 (2.96) T1 > T3***, T1 > T4*** 
T2 > T3***, T2 > T4*** 
   CPAP Non-compliant 57.59 (3.22) 52.07 (3.41) 55.03 (3.23) 53.46 (3.58) T1 > T2** 
    Overall Sample 56.86 (2.19) 53.86 (2.30) 50.88 (2.36) 50.25 (2.20) (Not interpreted) 
PSQI Global Severity Index      
   CPAP-compliant 13.76 (.77) 13.81 (.85) 9.60 (.77) 10.56 (.77) T1 > T3***, T1 > T4*** 
T2 > T3***, T2 > T4*** 
   CPAP Non-compliant 15.07 (.83) 13.86 (.90) 13.15 (.84) 12.13 (.88) T1 > T4** 
*p < .05. **p < .01. ***p < .001.   (table continues) 





Table 9 (continued)      
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by 
Group Status 
Outcome variable 











   Overall Sample 14.41 (.56) 13.84 (.62) 11.37 (.57) 11.35 (.58) (Not interpreted) 
PSQI-PTSD Addendum      
   CPAP-compliant 8.73 (1.13) 9.11 (1.22) 6.54 (1.13) 7.04 (1.13) (Not interpreted) 
   CPAP Non-compliant 9.28 (1.33) 8.06 (1.44) 7.32 (1.33) 8.44 (1.35) (Not interpreted) 
   Overall Sample 9.00 (.86) 8.58 (.93) 6.93 (.86) 7.74 (.87) T1 > T3**, T2 > T3** 
Nightmare Distress Scale       
    CPAP-compliant 29.73 (1.33) 31.41 (1.42) 32.54 (1.34) 32.01 (1.33) (Not interpreted) 
    CPAP Non-compliant 26.33 (1.49) 28.12 (1.59) 28.23 (1.48) 29.07 (1.49) (Not interpreted) 
    Overall Sample 28.03 (.98) 29.81 (1.03) 30.38 (.98) 30.54 (.98) T1 > T3**, T1 > T4** 
T1 > T2** 





Table 9 (continued)      
Follow-up Comparison of the Estimated Marginal Means from the Mixed-model Repeated Measures Analyses Separated by 
Group Status 
Outcome variable 











Epworth Sleepiness Scale total      
    CPAP-compliant 8.85 (1.16) 11.53 (1.24) 9.83 (1.17) 9.29 (1.17) T2 > T1** 
    CPAP Non-compliant 12.26 (1.26) 11.20 (1.31) 11.49 (1.24) 10.45 (1.27)  
    Overall Sample 10.55 (.86) 11.36 (.90) 10.66 (.85) 9.87 (.87) (Not interpreted) 
Conscientiousness Scale      
    CPAP-compliant 34.36 (1.47) 35.34 (1.56) 36.04 (1.48) 35.99 (1.47) (Not interpreted) 
    CPAP Non-compliant 30.63 (1.58) 31.49 (1.67) 32.14 (1.58) 31.65 (1.60) (Not interpreted) 
    Overall Sample 32.49 (1.08) 33.41 (1.14) 34.09 (1.08) 33.81 (1.09) (Not interpreted) 
Note: Significant pairwise comparisons by group status were only interpreted if indicated by a significant compliance status x 
time interaction for the respective model. Significant pairwise comparisons for the overall sample were only interpreted if 
indicated by a significant main effect for time for the respective model. T1 = Baseline assessment; T2 = Pretreatment 
assessment; T3 = Post-treatment 1 assessment; T4 = Post-treatment 2 assessment.  





 The purpose of this investigation was to expand on previous research that has 
examined the relationship between PTSD and sleep-disordered breathing. Specifically, 
this study prospectively examined posttraumatic stress symptoms following CPAP 
treatment for obstructive sleep apnea in a veteran population. We hypothesized that 
veterans compliant with their CPAP treatment would realize improvement in PTSD 
symptoms compared to pretreatment levels. Consistent with this hypothesis, and in line 
with previous retrospective work (Krakow et al. 2000; Youakim et al. 1998), our findings 
indicated that successful treatment of OSA with CPAP was associated with a subsequent 
reduction in PTSD symptoms. For veterans who were not compliant with CPAP 
treatment, no significant change in PTSD symptoms was observed.  
Given this pattern of results, we also conducted follow-up analyses to investigate 
the possibility that the influence of successful CPAP treatment on PTSD symptoms may 
be more pronounced on one or more of the specific PTSD symptom domains 
(reexperiencing, avoidance/numbing, and hyperarousal). Interestingly, our mixed model 
repeated measures results did not show statistically significant effects for any one specific 
PTSD symptom domain. Although the interpretability of these follow-up analyses was 
limited by low statistical power, these results suggest that improvement in OSA is 
associated with a generalized pattern of reduction in PTSD-related distress, not specific 
to any cluster of symptoms. This finding is somewhat less intuitive given that PTSD-
related sleep disturbance is specifically measured by the reexperiencing and hyperarousal 
symptom domains. One possible explanation for our findings is that OSA-related sleep 
disturbance may be functionally different than PTSD-related sleep disturbance. For 




sleep maintenance, and daytime fatigue (Phillipson, 1993; Wright et al., 1997) whereas 
the most commonly reported PTSD-related sleep dysfunction is difficulty with sleep 
initiation, sleep maintenance, and nightmares. Thus, the improvement in sleep processes 
associated with the successful treatment of obstructive sleep apnea may not overlap 
entirely with PTSD specific sleep disturbance. Another possibility is that the 
improvement in sleep quality associated with successful treatment of OSA may be 
associated with subsequent improvements in psychological functioning more generally 
and may not be entirely specific to PTSD. Although this latter hypothesis cannot be ruled 
out, it is less likely given the significantly elevated rates of OSA observed in samples of 
PTSD compared with general population samples (Krakow et al., 2000; Krakow et al., 
2001; Orr et al., 2010; Youakim et al., 1998).  
 Nonetheless, the present findings provide additional support to previous 
retrospective work suggesting that the successful treatment of OSA with CPAP may also 
reduce posttraumatic stress symptoms. These results are encouraging and may have 
important clinical implications. For example, treatment providers working with Veterans 
with PTSD may wish to incorporate appropriate OSA screening measures in addition to 
assessing for more behaviorally-based (PTSD-related) sleep disturbance. For veterans 
with untreated concurrent obstructive sleep apnea, PTSD symptoms may be exacerbated 
and sleep disturbance may not fully resolve with PTSD treatment alone. In addition, sleep 
processes have been proposed as an important factor in emotional memory processing 
and emotion regulation (van der Helm & Walker, 2009). Research suggests that the 
ability to encode new information as well as consolidate new information into long-term 




2004). Given that several current PTSD treatments hypothesize that symptom resolution 
occurs as a result of successful traumatic memory (re)processing (see Prolonged 
Exposure - Foa, Hembree, & Rothbaum, 2007; Cognitive Processing Therapy - Resick, 
Monson, & Chard, 2008), untreated concurrent conditions such as OSA that impact sleep 
processes may result in the reduced efficacy of these trauma processing oriented PTSD 
treatments. Treatment providers working with individuals with PTSD may enhance 
treatment outcomes by ensuring adequate identification and treatment compliance for 
physical sleep disorders like OSA. 
Unfortunately the research highlighted across these areas is ongoing and the 
mechanisms underlying the relationship between PTSD and OSA are unknown. At 
present, theories regarding the possible impact that OSA has on PTSD treatment are 
speculative. Substantially more research is needed to better define the possible 
mechanisms linking PTSD and OSA. It is possible that pre-existing or sub-threshold 
OSA may place individuals at greater risk to develop PTSD following a traumatic event 
or conversely, that individuals experiencing PTSD-related sleep disturbance may confer 
increased risk to develop OSA.   
Other Aspects of Psychological Functioning 
 In addition to PTSD symptoms, the current study prospectively evaluated several 
other aspects of psychological functioning among veterans receiving CPAP treatment for 
OSA. The first factor examined was self-reported sleep quality. We hypothesized that 
veterans who complied with the CPAP treatment would realize an improvement in 
perceived sleep quality relative to their respective pre-treatment ratings. Mixed-model 
analyses revealed a statistically significant effect of time, such that the overall sample 




somewhat surprising considering participants who were not CPAP-compliant would not 
be expected to see a reduction in sleep disturbance related to OSA. Although the 
improvement in sleep quality for CPAP non-compliant participants was somewhat less 
pronounced compared to the reduction for CPAP-compliant participants, it was 
statistically significant. A similar finding emerged for the second factor, PTSD-related 
sleep dysfunction, whereby the overall sample reported an improvement in PTSD-related 
sleep dysfunction from pre-to-post treatment. No significant differences were found for 
individuals that were CPAP-compliant compared to those who were non-compliant.  
One possible explanation for these findings is that participants may have altered 
their sleep habits in ways other than implementing the CPAP treatment. For example, all 
participants met with a member of the Neurology Clinic staff following their overnight 
sleep study. In addition to reviewing the results of the study and diagnostic 
considerations, these veterans were given information on improving sleep hygiene. 
Participants were also encouraged to make lifestyle changes, including losing weight and 
reducing alcohol consumption, as ways to decrease OSA severity. It is possible that 
participants, who chose not to utilize their CPAP treatment at the optimal therapeutic 
level, implemented other changes to their sleep routine or lifestyle which may have led to 
an improvement in perceived sleep quality. Although the current study did not evaluate 
behavioral modifications to the sleep routine, it is possible that CPAP utilization, 
improvements in sleep hygiene, or a combination of both resulted in the overall sample 
reporting increased sleep quality and decreased PTSD-related sleep dysfunction. Another 
possibility is that these findings are explained, simply by the phenomenon of regression 




Nonetheless, it is encouraging that in a sample of veterans diagnosed with OSA in 
addition to reported PTSD-related distress, that improvements in sleep can be realized. It 
is important to note that the current study was underpowered to detect differences 
between the groups. Future studies examining sleep indices among individuals with OSA 
and PTSD may wish to simultaneously monitor multiple aspects of sleep behavior in 
addition to CPAP compliance. In addition, a longer-term follow-up period would be 
helpful to determine whether or not the observed change in perceived sleep quality found 
in this study represent sustainable improvement across time. 
In addition to measures of sleep quality, this study examined a third factor, 
nightmare-related distress. We hypothesized that participants who were CPAP-compliant 
would report decreases in nightmare-related distress compared to pre-treatment report. 
Contrary to our hypothesis, results did not show a significant post-treatment improvement 
in nightmare-distress compared to pretreatment report. Of note, a significant increase in 
nightmare distress was reported from the baseline time point to pretreatment time point 
for the full sample; however, no significant differences were found between the 
pretreatment time point and either post-treatment time point. This finding was 
unexpected, given that previous cross-sectional research suggested that successful 
treatment of OSA with CPAP was associated with subsequent reductions in nightmare 
frequency and intensity (Krakow et al., 2000 & Youakim et al., 1998). One hypothesis 
proposed to explain these previous results is that the dysfunction in REM stage sleep 
attributed to OSA may be associated with an increase in nightmare experience for 
individuals with PTSD, as dreaming/nightmares is more frequently reported following 




1988). The current results do not support previous cross-sectional findings as no 
significant change in nightmare distress was observed for CPAP-compliant individuals 
who would be expected to demonstrate decreased awakenings during REM stage sleep 
following successful OSA treatment.  
Our findings are more consistent with a literature review conducted by Whittman 
and colleagues (2007) that concluded the occurrence of posttraumatic nightmares 
throughout the sleep cycle could not be explained by exclusively by altered REM sleep, 
thus the improvement in REM stage sleep density associated with CPAP treatment would 
not be expected to decrease nightmare distress related to the occurrence in nightmares 
across other sleep stages. It is important to note, however, that the Nightmare Distress 
Scale used in the current study measures nightmare-related distress and not the frequency 
in which nightmares occurred. Thus it is unclear if CPAP-compliant individuals in the 
sample may have experienced fewer nightmares producing an equivalent level of distress 
or if no change in the experience (frequency or intensity) of nightmares occurred overall. 
Furthermore, comparisons regarding change in nightmare distress from pre-to-post CPAP 
treatment may have limited by a low rate of nightmare endorsement at the baseline (M = 
31.39; SD = 9.88) and pretreatment (M = 29.54; SD = 9.00) time points. The rate of 
nightmare endorsement in this study may reflect the fact that the sample was not recruited 
based on a diagnosis of PTSD, but rather comprised of individuals that endorsed a range 
of posttraumatic stress symptoms.  
A final factor examined by this study was daytime somnolence. Subjectively 
reported daytime somnolence is a well-recognized symptom of untreated OSA. Research 




immediate reduction of daytime somnolence (Engelman et al., 1999; Jenkinson et al., 
1999; Kribbs et al., 1993). Our analyses were inconsistent with this line of research as 
results did find a change in daytime somnolence among CPAP-compliant participants. 
Although unanticipated, there are several possible explanations for the current results. 
First, as previously acknowledged, the current study was statistically underpowered and it 
is possible that if a daytime somnolence effect was present, it was too small for the 
current sample size to detect. Another possibility is that veterans in the CPAP-compliant 
group, although averaged ≤ 4 hours of use, may not have used their CPAP at the optimal 
therapeutic level every night. To this point, a study conducted by Kribbs and colleagues 
(1993) found that sleeping without CPAP for a single night resulted in almost complete 
reversal of daytime alertness gains derived from sleeping with CPAP. Follow-up 
inspection of the current sample revealed only 32% (n = 8) of the CPAP-compliant group 
reported utilizing the CPAP machine at the optimal therapeutic level for all 28 days of the 
follow-up period. A final possibility is that in a proportion of individuals with OSA and 
concurrent psychopathology, OSA may not be the principal cause of daytime somnolence 
(Antic et al. 2010). For example, in a general population sample, depression was found to 
be the most significant risk factor for daytime somnolence followed by BMI, age, sleep 
duration, diabetes, smoking, and lastly OSA (Bixler et al., 2005). Posttraumatic distress 
has not been directly examined in this regard; however, given the findings in the Bixler 
(2005) study, it is possible that daytime somnolence may be influenced by psychological 
conditions like PTSD and successful treatment of OSA may not alleviate more 





Cross-sectional Comparisons by CPAP Compliance Status  
The current study examined several factors thought to be associated with CPAP-
compliance and non-compliance. First we examined coping strategies and found that 
participants who were not CPAP-compliant endorsed using both the avoidant strategy of 
“venting” as well as “instrumental support” coping at significantly higher rates than 
CPAP-compliant participants.  In regard to venting, research has consistently linked 
avoidance style coping, including venting, to worse functional health outcomes including 
more severe PTSD symptoms (Aldwin & Revenson, 1987; Ashton et al., 2005; Penley, 
Tomaka & Wiebe, 2002; Tiet et al., 2006). Given this relationship, it is not surprising that 
we observed a correlation between higher levels of venting, CPAP-noncompliance, and 
sustained posttraumatic stress symptoms. Conversely, CPAP non-compliant participants 
also reported using a significantly higher level of instrumental support compared to 
CPAP-compliant participants. Instrumental support is considered to be a problem-focused 
(or approach-focused) coping strategy, which has been found to be associated with more 
positive health-related outcomes (Penley et al., 2002). Instrumental support largely 
consists of providing or seeking out tangible goods and services to assist with problem 
solving. Research examining spousal support in relation to CPAP compliance has found 
that an individual’s perception of spousal support only predicted compliance in 
individuals with severe OSA (Baron et al., 2011). Furthermore, this study found that 
perceived spousal pressure to use CPAP was associated with lower CPAP adherence 
rates. Although perceived support or pressure for CPAP use was not measured in the 




individuals warrant further investigation given the low rates of CPAP compliance 
observed in individuals with OSA.   
We also compared the endorsement of side effects associated with CPAP 
treatment among participants who were CPAP-compliant and non-compliant. Participants 
who were not CPAP-compliant reported significantly more problems across several areas 
including more problems with mask irritation and more CPAP-related sleep disturbance. 
These findings are consistent with previous research suggesting that greater endorsement 
of perceived CPAP side effects is positively associated with treatment noncompliance 
(Engleman, Martin, & Douglas, 1994).   
Methodological Considerations 
 This study had several notable limitations that should be considered when 
interpreting the current findings. As previously noted the sample size was small and 
likely limited the strength of our analytic approach to further examine change in PTSD 
symptoms and other aspects of psychological functioning. Previous research has 
demonstrated the difficulties of conducting longitudinal research with clinical 
populations (Coen & Patrick, 1996; Patel, Doku, & Tennakoon, 2003), which include 
difficulty recruiting and retaining participants. Although the high retention (95.7% at 
post-treatment 1 time point & 93.6% at post-treatment 2 time point) was a strength of the 
current study, we also sought to limit the impact of a small sample size and attrition by 
utilizing a mixed-modeling repeated measures statistical approach. Mixed-effect models 
provide a flexible framework for repeated measures analyses by utilizing all available 
data for each participant (Gueorguieva & Krystal, 2004). In addition, we took precautions 
to decrease the likelihood of detecting Type-I error by subjecting all post-hoc model 




 Another limitation of the current study is the lack of random assignment to study 
groups. This research study was designed to be quasi-experimental in nature in order to 
examine change in PTSD symptoms following CPAP treatment initiation for OSA as 
prescribed by the VA Neurology Sleep Clinic. Study groups (CPAP-compliant or CPAP 
non-compliant) were created following the conclusion of all data collection. Although 
random assignment to study groups is preferable, temporal and logistical restraints, in 
addition to the potential adverse health consequences of randomly assigning individuals 
to use or not use their CPAP treatment limited this study’s internal validity. To attend to 
this issue and potentially reduce threats to internal validity, the current study 
implemented a non-equivalent dependent variable as an additional measure of control on 
the impact of CPAP treatment on PTSD symptoms. Results found that participants did 
not report a change in conscientiousness level (non-equivalent dependent variable) from 
pre-to-post treatment. The lack of observed change in reported conscientiousness 
provided additional strength to the finding that successful treatment of OSA is associated 
with reductions in PTSD symptoms.   
Some additional limitations worth noting concern the generalizability and stability 
of current findings. Of the 489 participants invited to participate in this project, 71 
(14.5%) completed the baseline assessment. It is possible that this self-selected sample is 
not characteristic of the veteran population more generally. The sample was 
predominantly male (89.2%), thus it is unclear if these results would hold consistent 
among female veterans. Additionally, this study measured posttraumatic stress symptoms 
and not posttraumatic stress disorder. Although we used a well-known and validated 




clinical interviews to make formal PTSD diagnoses. Future studies should consider using 
a diagnostic measure of PTSD like the Clinician Administered PTSD Scale (Blake, 
Weathers, Nagy, & Kaloupek, 1995) as it would allow for diagnostic comparisons as well 
as a more nuanced examination of change in PTSD symptoms. In regard to CPAP 
compliance, participants in this study self-reported usage. In two cases, follow-up with 
objective measurement at three months indicated exaggerated CPAP use. Given the self-
reported follow-up period (1-month) represented approximately one-third of the objective 
SmartCard review (3-month), it is possible other participants may have exaggerated their 
use and went undetected. To avoid this limitation and increase sensitivity to the level of 
CPAP treatment adherence, future studies incorporate objective measurement of CPAP 
utilization across follow-up periods. Finally, the current study monitored participants 
across a four week follow-up period. The results suggested that CPAP compliance was 
associated with a decrease in posttraumatic stress symptoms; however, it is unclear if this 
reduction in symptoms would be maintained through continued CPAP utilization. Future 
studies should include longer follow-up periods in order to evaluate the stability of the 
current findings.  
Conclusions 
 Although few published studies have specifically examined the relationship 
between PTSD and obstructive sleep apnea, the available data suggests a strong 
association between these two diagnoses. The current study adds to this literature by 
demonstrating that successful treatment of OSA is associated with a reduction in PTSD 
symptoms over time. Future research should attempt to expand these findings by 1) 




attempt to elucidate the possible mechanisms underlying the relationship between PTSD 
and OSA.   
The current findings also have important clinical considerations. It appears that 
individuals with PTSD are at elevated risk for concurrent OSA and may benefit from 
identification and treatment of this physical sleep disorder. It is important for treatment 
providers working with individuals with PTSD or OSA to expand their assessment of 
sleep dysfunction to include both the evaluation of primary physical sleep disorders as 
well as secondary symptoms of a psychiatric diagnosis. Without a more complete 
diagnostic understanding of an individual’s sleep dysfunction (i.e., identifying and 
treating only physical sleep disorders or only psychiatric symptoms), it is possible that an 
individual will continue to experience sleep difficulty with the potential to undermine 
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